Loading…
EyePoint, Inc. is projected to rise to $13.13 by 2027, a +7% move from its current price of $12.25. EYPT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $11.86 | $12.25 | $12.65 | -0.01% |
| Aug 3 | $11.70 | $12.25 | $12.82 | -0.02% |
| Aug 4 | $11.58 | $12.25 | $12.95 | -0.04% |
| Aug 5 | $11.48 | $12.24 | $13.06 | -0.05% |
| Aug 6 | $11.39 | $12.24 | $13.16 | -0.06% |
| Aug 7 | $11.31 | $12.24 | $13.25 | -0.07% |
| Aug 8 | $11.24 | $12.24 | $13.33 | -0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.24 | $12.24 | $13.33 | -0.08% |
| Week 2 | $10.84 | $12.23 | $13.80 | -0.16% |
| Week 3 | $10.54 | $12.22 | $14.17 | -0.25% |
| Week 4 | $10.29 | $12.21 | $14.48 | -0.33% |
| Week 5 | $10.08 | $12.20 | $14.76 | -0.41% |
| Week 6 | $9.89 | $12.19 | $15.02 | -0.49% |
| Week 7 | $9.72 | $12.18 | $15.26 | -0.57% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
EyePoint, Inc. is a healthcare company that develops and commercializes therapeutics to improve the lives of patients with serious retinal diseases. Its pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME).
The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
EyePoint, Inc. (EYPT) is a healthcare company focused on developing therapeutics for retinal diseases, using its proprietary Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases that combines vorolanib with Durasert E, and it is in Phase 3 clinical trials for wet AMD and DME.
The company changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts. At present, EyePoint is trading at $12.86 with a market capitalization of $1.08B and holds a market rank of 2329.
A major floor 17.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.7% away) — a key level to hold.
The nearest ceiling, 21.1% above — a clean break opens room to run.
A major ceiling 30.0% above — clearing it would confirm fresh momentum.
Key EYPT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EYPT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $12.28 | Sell | $12.37 | Sell |
| MA 10 | $12.44 | Sell | $12.56 | Sell |
| MA 20 | $13.23 | Sell | $12.89 | Sell |
| MA 50 | $13.14 | Sell | $13.20 | Sell |
| MA 100 | $13.36 | Sell | $13.46 | Sell |
| MA 200 | $14.09 | Sell | $13.30 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.18 | Neutral |
| Stoch RSI (14) | 39.75 | Neutral |
| CCI (20) | -80.98 | Neutral |
| Williams %R (14) | -82.90 | Info |
| MACD (12,26,9) | -0.12 | Sell |
| ROC (12) | -11.55 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 17.10 | Buy |
| TRIX (15) | -0.22 | Sell |
| Awesome (5,34) | -1.10 | Sell |
| Ultimate (7,14,28) | 39.91 | Neutral |
| Momentum (10) | -1.05 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 12.25 | Sell |
| ADX (14) | 13.94 | Neutral |
| ATR (14) | 0.43 | Info |
The 30-day technical picture for EyePoint, Inc. is NEUTRAL. The RSI14 is 50, the SMA50 is $13.13, and the SMA200 is $14.10.
The 30-day range spans from $10.44 to $15.84, with a support level at $11.92 and a resistance level at $14.84.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $11.45 | $12.25 | $14.78 | 0% | Neutral | |
| $10.30 | $13.13 | $17.81 | +7% | Neutral | |
| $11.24 | $14.83 | $20.99 | +21% | Bullish | |
| $11.04 | $14.98 | $21.93 | +22% | Bullish | |
| $13.93 | $19.38 | $29.17 | +58% | Bullish | |
| $16.18 | $23.02 | $35.52 | +88% | Bullish | |
| $16.79 | $24.41 | $38.49 | +99% | Bullish | |
| $18.17 | $26.95 | $43.33 | +120% | Bullish | |
| $17.22 | $26.04 | $42.62 | +113% | Bullish | |
| $17.42 | $26.84 | $44.67 | +119% | Bullish | |
| $27.57 | $46.18 | $82.40 | +277% | Bullish | |
| $38.18 | $74.18 | $146.31 | +506% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $11.45 | $12.25 | $14.44 | +0.00% |
| September 2026 | $9.93 | $11.81 | $14.49 | -3.58% |
| October 2026 | $10.11 | $12.12 | $15.06 | +2.61% |
| November 2026 | $9.98 | $12.04 | $15.11 | -0.62% |
| December 2026 | $9.61 | $11.67 | $14.78 | -3.09% |
Click any year to see its month-by-month EYPT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, EYPT is projected to trade between $11.45 and $14.78, averaging $12.25 — a potential gain of 0% from today's $12.25. A consolidation phase looks the most probable path here.
EyePoint, Inc.'s 2027 outlook centres on $13.13, within a $10.30 to $17.81 range. That is up +7% on the projected 2026 average. That marks a +7% change versus current levels. Price action looks broadly range-bound.
By 2028, EYPT could reach as high as $20.99, with a base case around $14.83 and support toward $11.24 — roughly +21% from $12.25. Buyers look set to stay in control over this stretch.
Expect EYPT to range from $11.04 to $21.93 through 2029. The $14.98 average target implies a +22% move from current prices. That is up +1% on the projected 2028 average. Momentum favours further upside here.
The EYPT price prediction for 2030 points to an average of $19.38 (low $13.93, high $29.17) — a potential gain of +58% on today's $12.25. Buyers look set to stay in control over this stretch.
In 2031, EYPT is projected to trade between $16.18 and $35.52, averaging $23.02 — a potential gain of +88% from today's $12.25. That is up +19% on the projected 2030 average. Momentum favours further upside here.
EyePoint, Inc.'s 2032 outlook centres on $24.41, within a $16.79 to $38.49 range. That is up +6% on the projected 2031 average. That marks a +99% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, EYPT could reach as high as $43.33, with a base case around $26.95 and support toward $18.17 — roughly +120% from $12.25. Momentum favours further upside here.
Expect EYPT to range from $17.22 to $42.62 through 2034. The $26.04 average target implies a +113% move from current prices. That is -3% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The EYPT price prediction for 2035 points to an average of $26.84 (low $17.42, high $44.67) — a potential gain of +119% on today's $12.25. Momentum favours further upside here.
In 2040, EYPT is projected to trade between $27.57 and $82.40, averaging $46.18 — a potential gain of +277% from today's $12.25. That is up +72% on the projected 2035 average. Buyers look set to stay in control over this stretch.
EyePoint, Inc.'s 2050 outlook centres on $74.18, within a $38.18 to $146.31 range. That is up +61% on the projected 2040 average. That marks a +506% change versus current levels. Momentum favours further upside here.
Investing $1,000 in EYPT today (≈ 81.632653 EYPT) could be worth
$6,055.8
+$5,055.8 (+506%) by 2050 · US Dollar
Based on the average projected EYPT price of $74.18 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EYPTwould be worth at today's price.
$1,000 invested in EYPT on Jul 31, 2025 (≈ 101.832997 EYPT) would be worth
$1,247.45
+$247.45 (+24.7%) today · 1.25× · US Dollar
Based on a EYPT entry price of $9.82 vs. today's $12.25.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.19 | $1,004.92 | +0.5% |
| 1 month ago | $13.2 | $928.03 | -7.2% |
| 3 months ago | $13.34 | $918.29 | -8.2% |
| 6 months ago | $13.29 | $921.75 | -7.8% |
| 1 year ago | $9.82 | $1,247.45 | +24.7% |
| All time (5.0y) ago | $8.32 | $1,472.36 | +47.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EYPT forecast.
Our base-case forecast reaches $25.00 around 2033.
Implied market cap at $25.00: $2.1B
The multi-year forecast shows a bullish trajectory beyond 2026, with the averages and highs rising over time. The 2026 min $11.45, avg $12.86, max $15.54, ROI 0, sentiment NEUTRAL; 2027 min $10.93, avg $13.91, max $18.81, ROI 8.2, sentiment NEUTRAL; 2028 min $11.96, avg $15.73, max $22.20, ROI 22.3, sentiment BULLISH; 2029 min $11.83, avg $15.99, max $23.32, ROI 24.4, sentiment BULLISH; 2030 min $14.96, avg $20.74, max $31.09, ROI 61.2, sentiment BULLISH. From 2031 onward the forecast remains bullish with 2031 avg $24.59, 2032 avg $26.10, 2033 avg $28.90, 2034 avg $27.98, 2035 avg $28.94, 2040 avg $49.88, and 2050 avg $81.11; the corresponding max values reach $31.09 in 2030, $37.76 in 2031, $40.95 in 2032, $46.22 in 2033, $47.90 in 2035, $88.42 in 2040, and $158.74 in 2050.
The ROI figures scale to 91.2 (2031), 103 (2032), 124.7 (2033), 117.6 (2034), 125.1 (2035), 287.9 (2040), and 530.7 (2050). These are estimates, not guarantees, and sentiment is shown as bullish in the long horizon for most years.
Tap a question to reveal the answer.
In 2030, the forecast shows avg $20.74, min $14.96, max $31.09, ROI 61.2, sentiment BULLISH.
The forecast shows a path to higher prices with an avg of $20.74 in 2030 and a ROI of 61.2, and bullish sentiment from 2028 onward, with higher averages in 2040 ($49.88) and 2050 ($81.11). In earlier years, 2027 has avg $13.91 and ROI 8.2, with NEUTRAL sentiment.
Yes—the forecast’s max for 2050 is $158.74, which is above $100.
Current price is $12.86 and market cap is $1.08B. The market rank is 2329.
The 30-day range is $10.44 to $15.84; RSI14 is 50; SMA50 is $13.13; SMA200 is $14.10; support is $11.92 and resistance is $14.84. The annualized volatility is 60%.
EyePoint, Inc. Community Discussion
0Share your EyePoint, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.